HCPLive Network


Physicians Warned About Counterfeit Medical Devices
Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in Surgery and Medicine.
Asthma Drug May Help Those with Chronic Hives
Omalizumab (Xolair), used to treat moderate-to-severe allergic asthma, appears to offer relief to people with chronic hives who have not been helped by standard medications, new research published online July 21 in the Journal of Investigative Dermatology suggests.
Product News
FDA Approves Orphan Drug for Rare, Life-threatening Hereditary Angioedema
The US Food and Drug Administration recently approved a new drug aimed to aid the thousands of Americans affected by hereditary angioedema.
Are Body Lift Procedures Covered by Health Insurance?
Those who have lost a significant amount of weight are often left with sagging skin, and exercise is not the solution to that problem.
The Risks and Benefits of Scarless Thyroidectomy Techniques
A recent study emphasizes the importance of pitting the risks and rewards of traditional thyroidectomy against those of more recently developed techniques that also minimize scarring.
New Prognostic Factors May Be Useful in Staging Melanoma
New prognostic factors may be useful in predicting survival in patients with thin melanoma, according to research published online July 7 in the Journal of Clinical Oncology.
Product News
FDA Approves New Drug for Rheumatoid Arthritis
The US Food and Drug Administration recently announced its approval of a new medication for the treatment of rheumatoid arthritis.
Case Report Describes Allergic Contact Dermatitis from iPad
A case of allergic contact dermatitis from the nickel in an iPad has been described in a case report published online July 14 in Pediatrics.
Medical Schools Being Challenged to Find Training Sites
Medical schools are working to find solutions to ensure their students can continue to receive clinical training in spite of the escalating shortage of training sites, according to an article published by the American Academy of Family Physicians.
Secukinumab Effective in Moderate-to-Severe Psoriasis
For patients with moderate-to-severe plaque psoriasis, the fully human anti-interleukin-17A monoclonal antibody, secukinumab, is effective, according to research published online July 9 in the New England Journal of Medicine.
Condition Centers